Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clopidogrel

A J Coukell1, A Markham

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|November 14, 1997
PubMed
Summary
This summary is machine-generated.

Clopidogrel, an antiplatelet medication, effectively prevents ischemic events like stroke and heart attack in patients with atherosclerotic vascular disease. It offers superior efficacy compared to aspirin with a different side effect profile.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cabotegravir Plus Rilpivirine: First Approval.

Drugs·2020
Same author

Benralizumab: First Global Approval.

Drugs·2018
Same author

Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.

CNS drugs·2016
Same author

Erratum to: Pergolide: a review of its pharmacology and therapeutic use in Parkinson's disease.

CNS drugs·2016
Same author

Erratum to: Ziprasidone.

CNS drugs·2016
Same author

Obeticholic Acid: First Global Approval.

Drugs·2016
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Thrombosis Research

Background:

  • Clopidogrel is a thienopyridine drug that inhibits platelet aggregation.
  • It targets adenylate cyclase-coupled ADP receptors on platelets.
  • Animal models show clopidogrel reduces arterial and venous thrombi formation.

Purpose of the Study:

  • To compare the efficacy and safety of clopidogrel versus aspirin.
  • To evaluate clopidogrel's role in preventing ischemic events in atherosclerotic vascular disease.

Main Methods:

  • A large, well-controlled clinical trial (CAPRIE study) was conducted.
  • Patients with atherosclerotic vascular disease were randomized to receive either clopidogrel or aspirin.
  • Outcomes included prevention of ischemic stroke, myocardial infarction, and vascular death.

Related Experiment Videos

Main Results:

  • Clopidogrel demonstrated superior efficacy in preventing ischemic stroke, myocardial infarction, and vascular death compared to aspirin.
  • Clopidogrel treatment resulted in less frequent gastrointestinal upset, abnormal liver function, and gastrointestinal hemorrhage.
  • Increased incidence of rash and diarrhea was observed in the clopidogrel group; neutropenia and thrombocytopenia were rare and similar between groups.

Conclusions:

  • Clopidogrel is a more effective agent than aspirin for preventing major vascular events in patients with atherosclerotic vascular disease.
  • Clopidogrel presents a distinct safety profile with fewer gastrointestinal complications but a higher risk of rash and diarrhea.